KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax (2024 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Long-Term Deferred Tax for 2 consecutive years, with $957000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Deferred Tax fell 50.52% year-over-year to $957000.0, compared with a TTM value of $957000.0 through Dec 2025, down 50.52%, and an annual FY2025 reading of $957000.0, down 50.52% over the prior year.
  • Long-Term Deferred Tax was $957000.0 for Q4 2025 at Recursion Pharmaceuticals, roughly flat from $957000.0 in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $2.0 million in Q1 2025 and bottomed at $957000.0 in Q2 2025.